Abstract
Infectious diseases that are caused by pathogenic microbes such as bacteria, viruses, parasites or fungi remain the top major cause of death across the world, particularly in low income countries, and may be transmitted from person to person, or from insects or animals. In general, infectious diseases may be treated with antimicrobial agents including antibiotics, antiviral, antifungal or antiparasitic medications. The therapeutic application of antimicrobial drugs in the 20th century substantially contributed to the global control of infectious diseases worldwide. However, pathogenic microbes have evolved various mechanisms to render the antimicrobial drugs less effective. This has resulted in an increasing number of people infected with pathogenic microbes that are resistant to antimicrobial drugs, and in some cases leading to untreatable infections. Therefore, new antimicrobial drugs are urgently needed to prevent possible recurrence and emergence of previously treatable infectious diseases. In the past decades, protein kinase inhibitors have become an attractive area in the development of novel antimicrobial drugs. In the current review, we will describe the recent efforts in the development of microbial and host protein kinase-targeting inhibitors as potential antimicrobial drugs against HIV, tuberculosis and malaria.
Keywords: Protein kinase inhibitors, antimicrobial drugs, infectious diseases, tuberculosis, malaria, AIDS.
Current Pharmaceutical Design
Title:Protein Kinase Inhibitors as Potential Antimicrobial Drugs Against Tuberculosis, Malaria and HIV
Volume: 23 Issue: 29
Author(s): Yong Cheng*, Jeffrey S. Schorey, Cheng-Cai Zhang and Xuejuan Tan
Affiliation:
- Department of Biology, University of Notre Dame, 131 Galvin Life Science Center, Notre Dame, Indiana 46556,United States
Keywords: Protein kinase inhibitors, antimicrobial drugs, infectious diseases, tuberculosis, malaria, AIDS.
Abstract: Infectious diseases that are caused by pathogenic microbes such as bacteria, viruses, parasites or fungi remain the top major cause of death across the world, particularly in low income countries, and may be transmitted from person to person, or from insects or animals. In general, infectious diseases may be treated with antimicrobial agents including antibiotics, antiviral, antifungal or antiparasitic medications. The therapeutic application of antimicrobial drugs in the 20th century substantially contributed to the global control of infectious diseases worldwide. However, pathogenic microbes have evolved various mechanisms to render the antimicrobial drugs less effective. This has resulted in an increasing number of people infected with pathogenic microbes that are resistant to antimicrobial drugs, and in some cases leading to untreatable infections. Therefore, new antimicrobial drugs are urgently needed to prevent possible recurrence and emergence of previously treatable infectious diseases. In the past decades, protein kinase inhibitors have become an attractive area in the development of novel antimicrobial drugs. In the current review, we will describe the recent efforts in the development of microbial and host protein kinase-targeting inhibitors as potential antimicrobial drugs against HIV, tuberculosis and malaria.
Export Options
About this article
Cite this article as:
Cheng Yong *, Schorey S. Jeffrey, Zhang Cheng-Cai and Tan Xuejuan, Protein Kinase Inhibitors as Potential Antimicrobial Drugs Against Tuberculosis, Malaria and HIV, Current Pharmaceutical Design 2017; 23 (29) . https://dx.doi.org/10.2174/1381612823666170612122429
DOI https://dx.doi.org/10.2174/1381612823666170612122429 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
State of the Art in African Trypanosome Drug Discovery
Current Topics in Medicinal Chemistry Pharmacokinetic Evaluation of Callistemon viminalis Derived Natural Compounds as Targeted Inhibitors Against δ -Opioid Receptor and Farnesyl Transferase
Letters in Drug Design & Discovery Gold Coordination Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Acetohydroxyacid Synthase: A Target for Antimicrobial Drug Discovery
Current Pharmaceutical Design Dysprosium Hydroxide Nanowires Modified Electrode for Determination of Rifampicin Drug in Human Urine and Capsules by Adsorptive Square Wave Voltammetry
Current Pharmaceutical Analysis Use of Clays as Nanocarriers of First-Line Tuberculostatic Drugs
Current Drug Delivery Cathelicidins: Peptides with Antimicrobial, Immunomodulatory, Anti- Inflammatory, Angiogenic, Anticancer and Procancer Activities
Current Protein & Peptide Science Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives
Current Pharmaceutical Design Graphical Abstracts
Letters in Drug Design & Discovery Non-Covalent Proteasome Inhibitors
Current Pharmaceutical Design Development & Pharmaceutical Characterization of Isoniazid Loaded Solid Lipid Nanoparticle Drug Delivery Approach
Current Drug Therapy In Silico Assessment of Adverse Effects of a Large Set of 6-Fluoroquinolones Obtained from a Study of Tuberculosis Chemotherapy
Current Drug Safety Update on the Management of Spondyloarthritis in Asian Countries
Current Rheumatology Reviews Targeting Toll-like Receptors in Autoimmunity
Current Drug Targets Pharmacogenetic Polymorphisms in a Portuguese Gypsy Population
Current Pharmacogenomics and Personalized Medicine The role of interleukin 35 in atherosclerosis
Current Pharmaceutical Design A New Synthesis of Chiral Oxazolidinones from the Amino Acid L-serine
Letters in Organic Chemistry Synthesis of Marine Natural Products with Antimalarial Activity
Mini-Reviews in Medicinal Chemistry DNA Vaccine and the CNS Axonal Regeneration
Current Pharmaceutical Design Advanced in Silico Methods for the Development of Anti- Leishmaniasis and Anti-Trypanosomiasis Agents
Current Medicinal Chemistry